Effect of adalimumab treatment on lesions and inflammatory factors in patients with moderate-severe hidradenitis suppurativa.

OBJECTIVES

To investigate the efficacy and safety of adalimumab (ADA) in the treatment of hidradenitis suppurativa (HS).

METHODS

A retrospective analysis was conducted on the clinical data of 50 patients with HS. Patients were divided into ADA (n=30) and cyclosporine (CSA, n=20) groups. The Hidradenitis Suppurativa Clinical Response Criterion (HiSCR) and the International Hidradenitis Suppurativa Severity Score System (IHS4) were used to assess clinical efficacy. The Dermatology Life Quality Index (DLQI) was used to evaluate patients' quality of life, and peripheral blood inflammatory factor levels were measured. Safety was also assessed.

RESULTS

After treatment, all scores in both groups decreased significantly (all P<0.05); the decrease in IHS4 score in the ADA group was significantly greater than that in the cyclosporine (CSA) group (P<0.05). From week 2 to week 12 of treatment, there was a significant difference in the clinical response rate between the groups (P<0.05). At week 12, the Patient Global Assessment Relief Rate (PtGA RR) for skin pain in the ADA group was significantly higher than that in the CSA group (P<0.05). After treatment, the levels of inflammatory cells, NLRP3, and caspase-1 in both groups were significantly lower than those before treatment (P<0.05), with the ADA group showing a greater decrease than the CSA group (P<0.05). Some patients experienced dry mouth, abdominal pain, and scalp, which improved after symptomatic treatment. No relapse or secondary infection occurred.

CONCLUSION

ADA demonstrates good clinical efficacy and long-term safety in treating this population.